Observational studyCancer medicine2025
Direct Oral Anticoagulants Are Comparable to Low Molecular Weight Heparin at Sustaining the Circulating Extracellular Vesicle and Inflammatory Profiles of Cancer Associated Thrombosis Patients: An Observational Pilot Study.
Observational study in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating tumor cells and circulating tumor microemboli: role in venous thromboembolism in oncologic patients.Bioscience reports · 2026Review
- Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionCancer patients face a 4 to 7-fold higher risk of developing thrombotic events compared to individuals without cancer. This elevated risk is driven by the underlying tumour biology and the effects of cancer treatments, significantly increasing the mortality rates of these patients. While low molecular weight heparin (LMWH) is the gold standard anticoagulation, direct oral anticoagulants (DOACs) are emerging as effective alternatives. Recent clinical evidence indicates reduced recurrent VTE upon DOAC treatment compared to LMWH; however, there is limited understanding of the underlying mechanistic pathways. Of interest, extracellular vesicles (EVs), released from a multitude of cells including platelets and tumour cells, are known as potent intercellular communication mediators, capable of progressing coagulation, thrombosis, as well as tumour growth and metastasis.
methodsWe characterised the extracellular vesicles and inflammatory markers associated with hypercoagulability and thrombosis in cancer-associated thrombosis (CAT) patients, comparing those treated for 8 weeks with DOACs to those receiving LMWH. This pilot observational study recruited 28 CAT patients (21 baseline, 13 treated with DOACs, 8 treated with LMWH; 14 paired) and quantified their circulating, platelet-derived, and endothelial-derived EVs using Nanoparticle Tracking Analysis and flow cytometry. Proteomics was performed on the EV cargo and patient plasma, quantifying the inflammatory profiles of the patients under both treatment arms. RESULTS AND DISCUSSION: We demonstrated that DOAC treatment maintained hypercoagulable and prothrombotic EV profiles similar to LMWH treatment, showing a remarkably stable EV cargo proteome. Inflammatory profiles were also comparable between treatment arms, with a trend toward a DOAC-mediated reduction of circulating cytokines, highlighting potential anti-inflammatory effects.
conclusionThis pilot study demonstrates that DOACs sustain the circulating EV and inflammatory profiles to the same extent as LMWH, supporting this clinical shift in anticoagulant treatment in the cancer setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.